GlassScriptPhysician profile
Caroline Barbara Stevens
NPI 1992028039
$10,172.16
in general payments reported to CMS, 2019-2025
56 companies · $1,631 in 2025
The $1,631 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,658 · 2020: $727 · 2021: $725 · 2022: $1,515 · 2023: $1,525 · 2024: $2,391 · 2025: $1,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,547.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,672.66 | 2020-2025 | Duopa, Ubrelvy, Botox |
| Novartis Pharmaceuticals Corporation | $1,087.84 | 2019-2025 | |
| Mdd US Operations, LLC | $806.19 | 2019-2025 | Apokyn, Apokyn |
| Livanova USA, INC. | $669.84 | 2019 | |
| Acadia Pharmaceuticals INC | $580.65 | 2019-2025 | Nuplazid |
| Biogen, INC. | $527.71 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Allergan, INC. | $362.72 | 2019-2022 | |
| Pfizer INC. | $335.68 | 2019-2025 | |
| Ucb, INC. | $293.22 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Emd Serono, INC. | $268.07 | 2019-2023 | Mavenclad |
| Lundbeck LLC | $240.13 | 2020-2025 | Vyepti |
| Genzyme Corporation | $219.49 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $205.03 | 2019-2025 | Ultomiris, Soliris |
| Amgen INC. | $200.69 | 2019-2024 | Aimovig, Uplizna |
| Eisai INC. | $177.13 | 2019-2023 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $156.84 | 2023-2025 | Fycompa |
| Lilly USA, LLC | $155.91 | 2019-2025 | Amyvid, Emgality, Reyvow |
| Argenx US, INC. | $148.67 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Tg Therapeutics, INC. | $143.08 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $138.75 | 2020-2024 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $136.98 | 2019-2025 | Austedo Xr, Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $121.43 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $99.82 | 2020-2021 | |
| Tanabe Pharma America, INC. | $99.51 | 2019-2025 | Radicava |
| Sk Life Science, INC. | $93.59 | 2020-2025 | |
| Celgene Corporation | $88.41 | 2021-2023 | Zeposia |
| Avanir Pharmaceuticals, INC. | $86.61 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $85.46 | 2021-2023 | Epidiolex |
| Mallinckrodt Hospital Products INC. | $74.34 | 2021-2024 | Acthar |
| Medtronic, INC. | $71.78 | 2022-2025 | Sensight |
| Genentech USA, INC. | $71.59 | 2019-2024 | Ocrevus |
| Supernus Pharmaceuticals, INC. | $71.15 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $70.26 | 2019-2025 | Crexont, Rytary |
| Horizon Therapeutics Plc | $60.28 | 2022-2023 | Uplizna |
| Abbott Laboratories | $56.43 | 2023-2025 | Infinity, Proclaim |
| Axsome Therapeutics, INC. | $51.22 | 2025 | Symbravo, Sunosi |
| Banner Life Sciences, LLC | $50.22 | 2023-2024 | |
| Csl Behring | $44.18 | 2019-2023 | Hizentra |
| Harmony Biosciences LLC | $32.33 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $31.52 | 2021-2023 | Ponvory |
| Otsuka America Pharmaceutical, INC. | $27.65 | 2023 | Rexulti |
| Almatica Pharma LLC | $24.16 | 2021 | |
| Amylyx Pharmaceuticals, INC. | $23.02 | 2023 | Relyvrio |
| Alnylam Pharmaceuticals INC. | $22.43 | 2020 | |
| Aprecia Pharmaceuticals, LLC | $20.47 | 2020 | |
| Grifols USA, LLC | $19.67 | 2022 | |
| Neurelis, INC. | $17.87 | 2024 | Valtoco |
| Takeda Pharmaceuticals U.S.A., INC. | $17.83 | 2024 | Hyqvia |
| Merz Pharmaceuticals, LLC | $16.46 | 2025 | Inbrija |
| Acorda Therapeutics, INC | $15.89 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $15.66 | 2023 | Dysport |
| Promius Pharma LLC | $13.52 | 2019 | |
| Owp Pharmaceuticals, INC. | $13.01 | 2023 | Lamotrigine, Subvenite |
| Octapharma USA, INC. | $12.84 | 2023 | Panzyga |
| Elutia, INC. | $12.21 | 2019 | |
| Assertio Therapeutics, INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.